Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “

TTPH has been the topic of several other reports. Piper Jaffray Companies initiated coverage on Tetraphase Pharmaceuticals in a report on Monday, August 28th. They set an “overweight” rating and a $14.00 price target on the stock. Stifel Nicolaus restated a “buy” rating and set a $13.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. ValuEngine cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Sunday, September 17th. Finally, BMO Capital Markets lifted their price objective on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $12.96.

Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at 7.76 on Thursday. The company has a 50 day moving average of $6.79 and a 200-day moving average of $7.29. Tetraphase Pharmaceuticals has a 12 month low of $3.11 and a 12 month high of $9.93. The firm’s market capitalization is $396.17 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by ($0.07). The firm had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The business’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.47) earnings per share. Analysts predict that Tetraphase Pharmaceuticals will post ($2.73) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Tetraphase Pharmaceuticals, Inc. (TTPH) Rating Lowered to Hold at Zacks Investment Research” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/07/tetraphase-pharmaceuticals-inc-ttph-rating-lowered-to-hold-at-zacks-investment-research.html.

In related news, insider Jacques Dumas sold 17,500 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total value of $105,000.00. Following the transaction, the insider now directly owns 17,500 shares of the company’s stock, valued at $105,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.50% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the stock. UBS Group AG lifted its stake in shares of Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 387 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in Tetraphase Pharmaceuticals by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 874 shares during the period. American International Group Inc. lifted its stake in Tetraphase Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,486 shares during the period. Citadel Advisors LLC lifted its stake in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 2,496 shares during the period. Finally, Rhumbline Advisers lifted its stake in Tetraphase Pharmaceuticals by 5.7% in the second quarter. Rhumbline Advisers now owns 51,633 shares of the biopharmaceutical company’s stock valued at $368,000 after buying an additional 2,780 shares during the period. 41.73% of the stock is currently owned by institutional investors.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.